Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 56-68

  Toumpanakis, Christos ^a   Caplin, Martyn E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; LUTETIUM 177; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; TETRAXETAN; TETRAXETAN OCTREOTATE LU 177; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW SUPPRESSION; CARCINOID SYNDROME; DRUG EFFICACY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; NAUSEA AND VOMITING; NEPHROTOXICITY; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84873385177     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.006     Document Type: Article

References (102)

1. J.C. Yao, M. Hassan, A. Phan One hundred years after " carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
2. G. Rindi, R. Arnold, F.T. Bosman Nomenclature and classification of neuroendocrine neoplasms of the digestive system F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise, WHO classification of tumours in the digestive system ed 4. 2010 IARC Lyon 13 14
3. J.C. Reubi, J. Laissue, B. Waser Expression of somatostatin receptors in normal, inflammed and neoplastic human gastrointestinal tissues Ann NY Acad Sci 733 1994 122 137
4. M. Papotti, M. Bongiovanni, M. Volante Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 2002 461 475
5. G.R. Davis, R.C. Camp, P. Raskin, G.J. Krejs Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome Gastroenterology 78 1980 346 349
6. K. Dharmsathaphorn, R.S. Sherwin, S. Cataland, B. Jaffe, J. Dobbins Somatostatin inhibits diarrhea in the carcinoid syndrome Ann Intern Med 92 1980 68 69
7. W. Bauer, U. Briner, W. Doepfner SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1982 1133 1140
8. G. Sassolas, Y. Khalfallah, J.A. Chayvialle Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men J Clin Endocrinol Metab 68 1989 239 246
9. S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, A.B. Grossman Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr Relat Cancer 15 2008 701 720
10. J. Rubin, J. Ajani, W. Schirmer Octreotide acetate long-Acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 1999 600 606
11. P. Caron, A. Beckers, D.R. Cullen Efficacy of the new long-Acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly J Clin Endocrinol Metab 87 2002 99 104
12. C. Bousquet, C. Lasfargues, M. Chalabi Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy J Clin Endocrinol Metab 97 2012 727 737
13. L.K. Kvols, C.G. Moertel, M.J. O'Connell, A.J. Schutt, J. Rubin, R.G. Hahn Treatment of the malignant carcinoid syndrome Evaluation of a long-Acting somatostatin analogue N Engl J Med 315 1986 663 666
14. P. Tomassetti, M. Migliori, R. Corinaldesi, L. Gullo Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR Aliment Pharmacol Ther 14 2000 557 560
15. C. Toumpanakis, J. Garland, L. Marelli Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR Aliment Pharmacol Ther 30 2009 733 740
16. P. Ruszniewski, M. Ducreux, J.A. Chayvialle Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients Gut 39 1996 279 283
17. D. O'Toole, M. Ducreux, G. Bommelaer Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance Cancer 88 2000 770 776
18. P. Ruszniewski, S. Ish-Shalom, M. Wymenga Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide Neuroendocrinology 80 2004 244 251
19. M.S. Khan, F. El-Khouly, P. Davies, C. Toumpanakis, M.E. Caplin Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) Aliment Pharmacol Ther 34 2011 235 242
20. L.J. Hofland, S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 2003 28 47
21. E.T. Janson, K. Oberg Long-term management of the carcinoid syndrome Treatment with octreotide alone and in combination with alpha-interferon Acta Oncol 32 1993 225 229
22. K. Oberg, L. Kvols, M. Caplin Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Ann Oncol 15 2004 966 973
23. D.C. Metz, R.T. Jensen Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Gastroenterology 135 2008 1469 1492
24. M.H. Kulke, L.B. Anthony, D.L. Bushnell NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas Pancreas 39 2010 735 752
25. J.K. Ramage, A. Ahmed, J. Ardill Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Gut 61 2012 6 32
26. U. Plöckinger, B. Wiedenmann Neuroendocrine tumors Biotherapy Best Pract Res Clin Endocrinol Metab 21 2007 145 162
27. G.C. Nikou, C. Toubanakis, P. Nikolaou VIPomas: an update in diagnosis and management in a series of 11 patients Hepatogastroenterology 52 2005 1259 1265
28. S. Frankton, S.R. Bloom Gastrointestinal endocrine tumours Glucagonomas Baillieres Clin Gastroenterol 10 1996 697 705
29. R. Srirajaskanthan, M. McStay, C. Toumpanakis, T. Meyer, M.E. Caplin Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review Neuroendocrinology 89 2009 48 55
30. J. Soga, Y. Yakuwa Somatostatinoma/inhibitory syndrome: a stastical evaluation of 173 reported cases as compared to other pancreatic endocrinomas J Exp Clin Cancer Res 18 1999 13 22
31. S.W. Lamberts, W.W. de Herder, E.P. Krenning, J.C. Reubi A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome J Clin Endocrinol Metab 78 1994 17 19
32. K. von Werder, M. Losa, O.A. Müller, L. Schweiberer, R. Fahlbusch, E. Del Pozo Treatment of metastasising GRF-producing tumour with a long-Acting somatostatin analogue Lancet 2 1984 282 283
33. 2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas Endocr Relat Cancer 18 2011 287 300
34. M.C. Zatelli, E.C. degli Uberti Somatostatin receptors: from basic science to clinical approach - thyroid Dig Liver Dis 36 Suppl 1 2004 S86 S92
35. R. Srirajaskanthan, C. Toumpanakis, A. Karpathakis Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients Lung Cancer 65 2009 68 73
36. J.K. Ramage, A.H. Davies, J. Ardill Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut 54 Suppl 4 2005 iv1 iv16
37. S. Pyronnet, C. Bousquet, S. Najib, R. Azar, H. Laklai, C. Susini Antitumor effects of somatostatin Mol Cell Endocrinol 286 2008 230 237
38. M. Appetecchia, R. Baldelli Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives J Exp Clin Cancer Res 29 2010 19
39. J. Strosberg, L. Kvols Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors World J Gastroenterol 16 2010 2963 2970
40. B. Eriksson, J. Renstrup, H. Imam, K. Oberg High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects Ann Oncol 8 1997 1041 1044
41. P. Tomassetti, M. Migliori, L. Gullo Slow-release lanreotide treatment in endocrine gastrointestinal tumors Am J Gastroenterol 93 1998 1468 1471
42. A.N. Wymenga, B. Eriksson, P.I. Salmela Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms J Clin Oncol 17 1999 1111
43. S. Ricci, A. Antonuzzo, L. Galli Long-Acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors Am J Clin Oncol 23 2000 412 415
44. R. Arnold, M.E. Trautmann, W. Creutzfeldt Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 1996 430 438
45. L. Saltz, B. Trochanowski, M. Buckley Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 72 1993 244 248
46. M. di Bartolomeo, E. Bajetta, R. Buzzoni A study by the Italian Trials in Medical Oncology Group Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors Cancer 77 1996 402 408
47. S. Ricci, A. Antonuzzo, L. Galli Octreotide acetate long-Acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide Ann Oncol 11 2000 1127 1130
48. T. Aparicio, M. Ducreux, E. Baudin Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours Eur J Cancer 37 2001 1014 1019
49. S. Faiss, U. Räth, U. Mansmann Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 1999 469 476
50. S. Faiss, U.F. Pape, M. Böhmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
51. M. Ducreux, P. Ruszniewski, J.A. Chayvialle The antitumoral effect of the long-Acting somatostatin analog lanreotide in neuroendocrine tumors Am J Gastroenterol 95 2000 3276 3281
52. A. Bianchi, L. De Marinis, A. Fusco The treatment of neuroendocrine tumors with long-Acting somatostatin analogs: a single center experience with lanreotide autogel J Endocrinol Invest 34 2011 692 697
53. Massuti B, Alonso V, Marmol M, et al. Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive gastroenteropancreatic (GEP) and bronchopulmonary (BP) neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy. Paper presented at: 16th European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden.
54. I.M. Modlin, M. Pavel, M. Kidd, B.I. Gustafsson Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Aliment Pharmacol Ther 31 2010 169 188
55. Palazzo M, Lombard-Bohas C, Cadiot G, et al. Predictive factors of tumor control in patients with well-differentiated digestive endocrine carcinomas (WDEK) treated with lanreotide. Paper presented at: 19th United European Gastroenterology Week, 2011 October 22-26; Stockholm, Sweden.
56. A. Rinke, H.H. Müller, C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
57. Blumberg J, Liyanage N, Caplin M. The CLARINET study - assessing the effect of Lanreotide Autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Paper presented at: North American Neuroendocrine Tumor Symposium, 2011, October 20-22; Minneapolis, MN.
58. M. Pavel, E. Baudin, A. Couvelard ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157 176
59. S.V. Welin, E.T. Janson, A. Sundin High-dose treatment with a long-Acting somatostatin analogue in patients with advanced midgut carcinoid tumours Eur J Endocrinol 151 2004 107 112
60. M. Frank, K.J. Klose, M. Wied, N. Ishaque, C. Schade-Brittinger, R. Arnold Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors Am J Gastroenterol 94 1999 1381 1387
61. L. Kölby, G. Persson, S. Franzén, B. Ahrén Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 2003 687 693
62. R. Arnold, A. Rinke, K.J. Klose Octreotide versus octreotide plus interferon-Alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
63. J.C. Yao, A. Phan, P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 2008 1316 1323
64. J.C. Yao, C. Lombard-Bohas, E. Baudin Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
65. M.E. Pavel, J.D. Hainsworth, E. Baudin Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
66. E. Raymond, L. Dahan, J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
67. Valle J, Faivre S, Raoul JL, et al. Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS). Paper presented at: European Society for Medical Oncology, 2010, 8-12 October; Milan, Italy.
68. G. Delle Fave, D.J. Kwekkeboom, E. Van Cutsem ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms Neuroendocrinology 95 2012 74 87
69. P. Tomassetti, M. Migliori, G.C. Caletti, P. Fusaroli, R. Corinaldesi, L. Gullo Treatment of type II gastric carcinoid tumors with somatostatin analogues N Engl J Med 343 2000 551 554
70. V. Fykse, A.K. Sandvik, G. Qvigstad, S.E. Falkmer, U. Syversen, H.L. Waldum Treatment of ECL cell carcinoids with octreotide LAR Scand J Gastroenterol 39 2004 621 628
71. D. Campana, F. Nori, R. Pezzilli Gastric endocrine tumors type I: treatment with long-Acting somatostatin analogs Endocr Relat Cancer 15 2008 337 342
72. S. Grozinsky-Glasberg, G. Kaltsas, C. Gur Long-Acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours Eur J Endocrinol 159 2008 475 482
73. C.S. Jianu, R. Fossmark, U. Syversen, Ø. Hauso, V. Fykse, H.L. Waldum Five-year follow-up of patients treated for 1 year with octreotide long-Acting release for enterochromaffin-like cell carcinoids Scand J Gastroenterol 46 2011 456 463
74. L. Zhang, J. Ozao, R. Warner, C. Divino Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor World J Surg 35 2011 1879 1886
75. M. Kidd, I.M. Modlin, J.W. Black, M. Boyce, M. Culler A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation Regul Pept 143 2007 109 117
76. Kvols L, Wiedenmann B, Oberg K, et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. Paper presented at: American Society of Clinical Oncology GI Cancers Symposium 2006, 18-20 June; Atlanta, GA.
77. A. Saveanu, G. Gunz, H. Dufour Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab 86 2001 140 145
78. Y. Zambre, Z. Ling, M.C. Chen Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5 Biochem Pharmacol 57 1999 1159 1164
79. M.D. Culler Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors Horm Metab Res 43 2011 854 857
80. M. Arvigo, F. Gatto, M. Ruscica Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines J Endocrinol 207 2010 309 317
81. T. Florio, F. Barbieri, R. Spaziante Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human nonfunctioning pituitary adenomas: a multi-center study Endocr Relat Cancer 15 2008 583 596
82. Lesage C, Seymour C, Urbanavicious V, Beckers A, Kazanavicious G, Colao A. A phase II exploratory study of BIM23A760 in acromegalic patients: preliminary results of safety and efficacy after a single-dose administration. Paper presented at: 91st Annual Meeting of the Endocrine Society, 2009, 10-13 June; Washington, DC.
83. D. O'Toole, A. Saveanu, A. Couvelard The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur J Endocrinol 155 2006 849 857
84. M. Ginj, H. Zhang, B. Waser Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc Natl Acad Sci U S A 103 2006 16436 16441
85. D. Wild, M. Fani, M. Behe First clinical evidence that imaging with somatostatin receptor antagonists is feasible J Nucl Med 52 2011 1412 1417
86. J.J. Teunissen, D.J. Kwekkeboom, R. Valkema, E.P. Krenning Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours Endocr Relat Cancer 18 Suppl 1 2011 S27 S51
87. E.S. Delpassand, J. Sims-Mourtada, H. Saso Safety and efficacy of radionuclide therapy with high-Activity In-111 pentetreotide in patients with progressive neuroendocrine tumors Cancer Biother Radiopharm 23 2008 292 300
88. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36 2006 147 156
89. 90Y- edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
90. F. Forrer, R. Valkema, D.J. Kwekkeboom, M. de Jong, E.P. Krenning Neuroendocrine tumors Peptide receptor radionuclide therapy Best Pract Res Clin Endocrinol Metab 21 2007 111 129
91. J.B. Cwikla, A. Sankowski, N. Seklecka Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann Oncol 21 2010 787 794
92. Toumpanakis C, Quigley A, Srirajaskanthan R, et al. 90-Yttrium-DOTA- octreotate for the treatment of advanced neuroendocrine tumors. Paper presented at: American Society of Clinical Oncology 2009, 29 May-2 June; Orlando, FL.
93. D.J. Kwekkeboom, W.H. Bakker, B.L. Kam Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate Eur J Nucl Med Mol Imaging 30 2003 417 422
94. D.J. Kwekkeboom, W.W. de Herder, B.L. Kam Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
95. M.A. Muros, M. Varsavsky, P. Iglesias Rozas Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues Clin Transl Oncol 11 2009 48 53
96. 177Lu- [DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy Cancer 116 4 Suppl 2010 1084 1092
97. D.J. Kwekkeboom, J.J. Teunissen, W.H. Bakker Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors J Clin Oncol 23 2005 2754 2762
98. 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 35 2008 743 748
99. 177Lu-DOTA]-TOC in neuroendocrine cancers J Clin Oncol 30 2012 1100 1106
100. 90Y-labeled somatostatin analogs J Nucl Med 46 Suppl 1 2005 13S 17S
101. J.J. Teunissen, D.J. Kwekkeboom, M. de Jong, J.P. Esser, R. Valkema, E.P. Krenning Endocrine tumours of the gastrointestinal tract Peptide receptor radionuclide therapy Best Pract Res Clin Gastroenterol 19 2005 595 616
102. G. Arora, J. Shukla, S. Ghosh, S.K. Maulik, A. Malhotra, G. Bandopadhyaya PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose PLoS One 7 2012 e34019